Please use this identifier to cite or link to this item:
http://localhost:8080/xmlui/handle/123456789/9343
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Huang, Ching-I | - |
dc.contributor.author | Liang, Po-Cheng | - |
dc.contributor.author | a, Yu-Ju Wei | - |
dc.contributor.author | Tsai, Pei-Chien | - |
dc.contributor.author | Hsu, Po-Yao | - |
dc.contributor.author | Hsieh, Ming-Yen | - |
dc.date.accessioned | 2024-12-19T04:57:07Z | - |
dc.date.available | 2024-12-19T04:57:07Z | - |
dc.date.issued | 2023-06 | - |
dc.identifier.citation | Original Article | en_US |
dc.identifier.uri | http://localhost:8080/xmlui/handle/123456789/9343 | - |
dc.description.abstract | Abstract Objectives: Gaps in linkage-to-care remain the barriers toward hepatitis C virus (HCV) elimination in the directly-acting-antivirals (DAA) era, especially during SARS CoeV2 pandemics. We established an outreach project to target HCV micro-elimination in HCVhyperendemic villages. Methods: The COMPACT provided “door-by-door” screening by an “outreach HCV-checkpoint team” and an “outreach HCV-care team” for HCV diagnosis, assessment and DAA therapy in Chidong/Chikan villages between 2019 and 2021. Participants from neighboring villages served as Control group. Results: A total of 5731 adult residents participated in the project. Anti-HCV prevalence rate was 24.0% (886/3684) in Target Group and 9.5% (194/2047) in Control group (P < 0.001). The HCV-viremic rates among anti-HCV-positive subjects were 42.7% and 41.2%, respectively, in Target and Control groups. After COMPACT engagement, 80.4% (304/378) HCV-viremic subjects in the Target group were successfully linked-to-care, and Control group (70% (56/80), P Z 0.039). The rates of link-to-treatment and SVR12 were comparable between Target (100% and 97.4%, respectively) and Control (100% and 96.4%) groups. The community effectiveness was 76.4% in the COMPACT campaign, significantly higher in Target group than in Control group (78.3% versus 67.5%, P Z 0.039). The community effectiveness decreased significantly during SARS CoeV2 pandemic in Control group (from 81% to 31.8%, P < 0.001), but not in Target group (80.3% vs. 71.6%, P Z 0.104). Conclusions: The outreach door-by-door screen strategy with decentralized onsite treatment programs greatly improved HCV care cascade in HCV-hyperendemic areas, a model for HCV elimination in high-risk marginalized communities in SARS CoeV2 pandemic. | en_US |
dc.language.iso | en_US | en_US |
dc.subject | Microelimination | en_US |
dc.subject | DAA | en_US |
dc.subject | Hyperendemic areas | en_US |
dc.subject | COMPACT | en_US |
dc.subject | SARS CoeV2 | en_US |
dc.subject | Pandemic | en_US |
dc.title | A people-centered decentralized outreach model toward HCV micro-elimination in hyperendemic areas: COMPACT study in SARS CoeV2 pandemic | en_US |
dc.type | Article | en_US |
Appears in Collections: | VOL 56 NO 3 2023 |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
586-597.pdf | 869.57 kB | Adobe PDF | View/Open |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.